Navigation Links
Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
Date:11/12/2013

d delivered within the eye to maintain intraoperative mydriasis (pupil dilation), to reduce surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "wi
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Corporation Reports Third Quarter 2013 Financial Results
2. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
3. Omeros to Present at the 12th Annual Needham Healthcare Conference
4. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
5. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
6. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
7. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
8. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
9. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
10. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
11. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Staying true to their ... a digital product that makes the world a better ... Biological Standards Institute (GBSI) to redesign their website ( ... most importantly, strategy-based. , "Biomedical research is not always ... less to promote it in a narrative way on ...
(Date:4/21/2015)... 21, 2015 Invetech , a ... automation, and contract manufacturing, and  NanoCellect Biomedical, ... and cell sorting technology for life science researchers, ... flow cytometry platform. Headquartered in ... developed a microchip-based cell sorting technology. NanoCellect,s flow ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading provider ... Josh Forsythe as VP of Marketing. Mr. Forsythe ... a significant expansion in its commercial operations over the last ... " Josh Forsythe is a tremendous addition to ... MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing software ...
(Date:4/21/2015)... RESEARCH TRIANGLE PARK, N.C. , April 21, 2015 ... announced today that it will release its first quarter ... 28, 2015. United Therapeutics will host a ... a.m. Eastern Time.  The teleconference is accessible by dialing ... the teleconference will be available for one week and ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... processing revenues in the third, quarter of 2007 increased 25 percent ... ... Oct. 11 CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... revenues for the third quarter,of 2007 were approximately $21.9 million compared ...
... Challenges and Opportunities to Realize ... Critical Path Initiative Goals, ... PHST), a leading provider of software,strategic consulting, and regulatory services ... senior vice,president and chief technology officer, has been invited to ...
... Solstice Neurosciences, Inc.,("Solstice") announced the appointment of ... Smith will serve as Executive Chairman replacing James,Thomas, ... Chairman since Solstice,was founded in July 2004. ... expertise to Solstice that will be invaluable in ...
Cached Biology Technology:CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 2Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 3Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc. 2
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/18/2015)... SPRINGS, Florida , March 18, 2015 ... well as businesses, new revolutionary smart wallets and apps continue ... pace.  Companies currently entrenched in the mobile payment industry in ... Alibaba Group Holding Ltd. (NYSE: BABA ), Apple ... GOOG ) and Facebook Inc. (NASDAQ: FB ...
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... your average persons idea of a good time, but for ... I think worms are totally cool, like humans only simpler ... working with the invertebrates is what will bring Dr. Fraser ... he will present some of his research findings in a ...
... ALBUQUERQUE, N.M. As Americans demand new and cleaner ... turning to algae as a promising new fuel source. ... nation,s reliance on imported oil while contributing to rural ... that algae-based biofuels could displace large volumes of diesel ...
... The American Association for Dental Research (AADR) has announced ... Chilton Fellowship in Clinical Research recipient. He will be ... Washington, DC, March 3, 2010. Currently, Dawson is ... the Delta Dental of Kentucky Clinical Research Center, in ...
Cached Biology News:The impact of genomics 2Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 2Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 3Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 4
...
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: